Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis

Published in: Neurology, v. 68, no. 18, May 1, 2007, p. 1524-1528

Posted on RAND.org on December 31, 2006

by E. Ray Dorsey, Joel P. Thompson, Katia Noyes, Andrew W. Dick, Robert G. Holloway, S. R Schwid

Read More

Access further information on this document at www.neurology.org

This article was published outside of RAND. The full text of the article can be found at the link above.

Using published data, the authors quantified the risk and benefits of natalizumab in relapsing multiple sclerosis using quality-adjusted life years (QALYs) as a metric. Over the first 2 years of therapy, the negative health effects from progressive multifocal leukoencephalopathy were small (loss of 0.001 QALYs) relative to the positive effects on relapses and disability resulting in 0.033 QALYs (12 quality-adjusted days) gained. For context, the authors performed an analogous calculation for interferon beta-1a, which also had a net health benefit of 0.033 QALYs (12 quality-adjusted days).

This report is part of the RAND Corporation external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.